Document is current

Article History

Received: 24 March 2025

Accepted: 29 April 2025

First Online: 23 May 2025

Declarations

:

: This study was performed in line with the principles of the Declaration of Helsinki. The study was approved by the institutional review board of the University Medical Centre Groningen (registration number: 17471).

: Informed consent was obtained from all individual participants included in the study.

: HSA Tingen was reimbursed for traveling costs by Pfizer and Alnylam. M Berends was reimbursed for traveling costs by Pfizer and Alnylam. A Tubben has nothing to declare. P van der Meer is supported by grant from the European Research Council (ERC CoG 101045236, DISSECT-HF) and received consultancy fees and/or grants from Novartis, Pharmacosmos, Vifor Pharma, Astra Zeneca, Pfizer, Pharma Nord, BridgeBio, Novo Nordisk, Daiichi Sankyo, Boehringer Ingelheim, and Ionis, all paid to the institute. RHJA Slart is supported by unrestricted research grants of Siemens Healthineers and Pfizer, all paid to the institute. J Bijzet has nothing to declare C Kimmich was reimbursed for traveling costs by Gilead and Janssen and received consultancy fees from Amgen, AstraZeneca, EUSA Pharma, Gilead, GSK, Incyte, Janssen, Pfizer and Sanofi-Aventis. C Knackstedt has received speaker honoraria from Pfizer and consulting fees from Bayer, Pfizer, Novartis, BMS, and Alnylam, all paid to the institute. PA van der Zwaag received consultancy fees from Pfizer, Alnylam and Novartis, all paid to the institute. FLH Muntinghe has nothing to declare EJ Houwerzijl has nothing to declare. BPC Hazenberg was reimbursed for traveling costs by Pfizer. HLA Nienhuis received consultancy fees from Pfizer, Alnylam and Novartis, all paid to the institute.